SHIKARI® (Q-MIR) Mirikizumab ELISA
MIR-FD-OMV
Enzyme immunoassay for the quantitative determination of Mirikizumab (Omvoh®) in human serum and plasma.
This kit has been especially developed for the specific and quantitative determination of Mirikizumab in serum and plasma samples between the Cmin and Cmax range of concentrations. Mirikizumab Drug Bank Accession Number is DB14910
All SHIKARI® ELISA kits are produced under ISO 13485 quality system.
This kit has been especially developed for the specific and quantitative determination of Mirikizumab in serum and plasma samples between the Cmin and Cmax range of concentrations. Mirikizumab Drug Bank Accession Number is DB14910
Mirikizumab is a humanized IgG4 monoclonal antibody targeting the p19 subunit of the proinflammatory cytokine interleukin-23 (IL-23). This molecule was produced entirely in mice as mouse antibody clone 9F2 and humanized via grafting onto the human IgG4 Fab region. It was developed by Eli Lilly and is intended to treat ulcerative colitis.
All SHIKARI® ELISA kits are suitable for biosimilar work.All SHIKARI® ELISA kits are produced under ISO 13485 quality system.
Research Use Only (RUO)
For technical inquiry, IFU and other relevant documents please contact techsupport@matriksbiotek.com
| Required Volume (µl) | 10 |
| Total Time (min) | 135 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 0,6 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
| Assay type | Quantitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
